CagriSema
MODERATE EVIDENCEAlso known as: Cagrilintide + Semaglutide
Investigational combination — not approved; contains an analogue of an approved drug class
Educational Overview
A combination preparation of an amylin analogue with a GLP-1 receptor agonist, under clinical investigation for metabolic research.
Research Mechanism
Combines amylin and GLP-1 receptor pathways studied for additive effects on satiety and glycaemic signalling in trial settings.
Areas of Study
- Combination metabolic trials
Safety Considerations
Investigational combination. Semaglutide is the active ingredient of FDA-approved products; compounded and research-supplied versions are NOT approved and are not interchangeable with approved medicines. Research material only.
Frequently Asked Questions
Is this approved for human use?
No. This material is supplied for laboratory research use only by qualified businesses and institutions. It is not a medicine and is not for human or veterinary consumption.
Do you provide purity documentation?
Certificates of analysis are available to approved accounts. Contact our team for batch-specific documentation.
References
References pending editorial review
We publish citations only after a qualified reviewer has verified them against the primary literature. We do not list references we have not checked. (1 queued.)
Last reviewed: 2026-07-23 · Status: in_review · References verified by editorial review before publication.
Disclaimer: Educational only. Not medical advice, diagnosis, or treatment. For research and educational purposes. Consult a licensed medical professional.